Danish Commercial Services Stock News

In late December 2025, Novo Nordisk secured FDA approval for and has now launched in the U.S. the Wegovy pill, the first once-daily oral GLP-1 therapy for chronic weight management and cardiovascular risk reduction, supported by Phase 3 data showing substantially greater weight loss than placebo when combined with diet and exercise. The pill’s broad rollout through major pharmacies, telehealth partners such as Ro, LifeMD, Weight Watchers, and platforms like GoodRx and NovoCare meaningfully...

When you see that almost half of the companies in the Entertainment industry in Denmark have price-to-sales ratios (or...

When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") below 16x, you may consider...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

ISS (CPSE:ISS) has launched a new share buyback programme of up to DKK 3,000 million over 12 months, drawing attention to how the facility services group is handling excess cash and its share capital structure. See our latest analysis for ISS. At a share price of DKK 220.6, ISS has logged an 11.30% 90 day share price return, while its 1 year total shareholder return of 68.80% points to strong momentum that this buyback announcement may be reinforcing rather than reversing. If this kind of...

Genmab A/S recently reaffirmed its 2025 earnings guidance and decided to discontinue further clinical development of acasunlimab after evaluating its portfolio and the evolving competitive landscape. By reallocating resources toward late-stage assets such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina-S), Genmab is sharpening its late-stage antibody pipeline focus. We will now examine how concentrating capital on EPKINLY, petosemtamab and Rina-S could reshape Genmab’s...

In early January 2026, Ørsted and its partner Skyborn Renewables filed a legal complaint in the US challenging the Trump administration’s suspension of the lease for their Revolution Wind offshore project, a roughly US$5.00 billion development that is about 87% complete after a nine-year permitting process. The dispute places one of the most advanced US offshore wind projects, and its planned 2026 power deliveries and thousands of associated jobs, at the center of a high‑stakes test of...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Novo Nordisk (CPSE:NOVO B) has been quietly grinding higher, with the stock up around 7% over the past month, even after a weaker stretch in the past 3 months and year. See our latest analysis for Novo Nordisk. That recent 6.7% one month share price return looks more like a short term reset than a full trend change, given the 1 year total shareholder return of minus 45.1% and 5 year total shareholder return still up 67.2%. This suggests long term believers have been rewarded even as momentum...

Outlook for Vestas Wind Systems Shares After Recent Gains Vestas Wind Systems (CPSE:VWS) has quietly staged a strong comeback, with the stock up about 12% over the past month and roughly 40% in the past 3 months, drawing fresh investor attention. See our latest analysis for Vestas Wind Systems. That recent rebound comes after a tougher few years, with a 1 year total shareholder return of about 72% contrasting sharply with weaker 3 and 5 year total shareholder returns. This suggests momentum...

FLSmidth (CPSE:FLS) has quietly outperformed the Danish market over the past year, and the latest leg higher is catching investor attention as they reassess the company’s mix of shrinking revenue but improving profitability. See our latest analysis for FLSmidth. At around DKK 450 per share, FLSmidth’s recent 1 month share price return of roughly 11 percent contrasts with a weaker 3 month patch, while a 1 year total shareholder return near 29 percent suggests momentum is still broadly...

With a price-to-sales (or "P/S") ratio of 3.5x Zealand Pharma A/S ( CPH:ZEAL ) may be sending very bullish signals at...

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...

With a price-to-earnings (or "P/E") ratio of 37.7x Ambu A/S ( CPH:AMBU B ) may be sending very bearish signals at the...

RIAS A/S ( CPH:RIAS B ) is reducing its dividend from last year's comparable payment to DKK26.00 on the 26th of...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Pandora fair value estimate is kr.1,082 Current share price of...

Key Insights Given the large stake in the stock by institutions, Demant's stock price might be vulnerable to their...

Even if it's not a huge purchase, we think it was good to see that David Hojelsen, the Chief Technology Officer of...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Short term moves and recent performance A.P. Møller - Mærsk (CPSE:MAERSK B) has quietly climbed over the past month, even without a clear headline catalyst, leaving investors wondering whether the recent strength is sustainable or merely sentiment driven. See our latest analysis for A.P. Møller - Mærsk. That recent upswing fits into a broader recovery story, with the share price up solidly over the past quarter and year to date. A strong one year total shareholder return suggests momentum is...

Brd. Klee A/S ( CPH:KLEE B ) has announced that it will pay a dividend of DKK85.14 per share on the 23rd of January...

Coloplast has recently announced upcoming changes to its Executive Leadership Team, with long-serving leaders in People & Culture and Interventional Urology set to depart and successors, including incoming Interventional Urology head Kevin Hardage from Teleflex, lined up to ensure business continuity. These leadership shifts, particularly in the Interventional Urology division and the global People & Culture function, could influence how effectively Coloplast executes its reorganisation,...